Abstract 5520
Background
Chemotherapy‐induced nausea and vomiting (CINV) continue to be a clinical problem, particularly in the delayed phase. CINV lack of control worsens the quality of life of patients and it is associated with complications increasing costs for healthcare services. CINV app is a free service addressed to patients treated with emetogenic chemotherapy (CT), empowering patients to report CINV impact in life and relevant information. This study aims to evaluate the usability and acceptability of a smartphone app to improve CINV management in patients receiving CT.
Methods
We used 4‐dimensions test (content, graphic design, navigation and clinical utility) to evaluate APP’s usability and acceptability. Clinical and technical researchers worked together to develop the app’s test. 44 oncology nurses of 33 representative Spanish hospitals were invited to participate (from 31st January to 5th April 2019) enrolling a total amount of 116 oncology patients for testing purposes. After using the app for a chemo cycle the patient was asked to fulfil an online usability test.
Results
Described in the table.Table: CN2
Average of patients that agree for each dimension
Variables | Results (%) |
---|---|
Contents | 81% |
Navigation | 79% |
Graphic design | 83% |
Utility | 90% |
N = 116 Oncology chemo patients level agreement 83% of patients consider this app useful for them and 86% believe it would help to improve CINV management. 94% of patients would recommend it to other patients.
Conclusions
The CINV app addresses main concerns for patients receiving chemotherapy such as the clinical situation and individual emetic risk of patient or complexity of the prescribed antiemetic regimen and impact of CINV in patients daily life. By soliciting feedback from oncology patients, we ensured that the app was acceptable and beneficial for them although some improvement points were suggested. Reporting of symptoms after CT enhances CINV management, self‐care, and participation without being a burden to patients, indicating that app can be used in clinical practice by patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vifor Pharma España SL.
Funding
Vifor Pharma España SL.
Disclosure
P. Fernandez: Advisory / Consultancy, advisor activities: Vifor Pharma España. All other authors have declared no conflicts of interest.
Resources from the same session
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract
5529 - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Presenter: Robert Tauber
Session: Poster Display session 3
Resources:
Abstract